Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | GYS1 | P13807 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12737125 | 0.95 | FFAR4 (0.44) | FFAR1FFAR4MAOBS1PR1S1PR3 | |
| SCHEMBL12740577 | 0.92 | MAPT (0.46) | FFAR1FFAR4S1PR1S1PR3 | |
| SCHEMBL12740170 | 0.91 | S1PR1 (0.39) | FFAR1FFAR4S1PR1S1PR3PPARD | |
| SCHEMBL14767038 | 0.91 | FFAR1 (0.45) | FFAR1FFAR4MAOBPPARDCACNA1C | |
| SCHEMBL12740573 | 0.90 | FFAR1 (0.42) | FFAR1FFAR4MAOBPPARDCACNA1C | |
| SCHEMBL12740586 | 0.89 | FFAR1 (0.44) | FFAR1FFAR4MAOBPPARDCACNA1C | |
| SCHEMBL12740561 | 0.89 | FFAR4 (0.43) | FFAR1FFAR4MAOBGYS1PTGES | |
| SCHEMBL14766910 | 0.89 | FFAR1 (0.43) | FFAR1FFAR4S1PR1S1PR3PPARD | |
| SCHEMBL10302524 | 0.88 | GABRA1 (0.40) | FFAR1FFAR4MAOBPPARDCACNA1C | |
| SCHEMBL12740560 | 0.88 | FFAR4 (0.50) | FFAR1FFAR4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR1 247/4885FFAR4 546/4885MAOB 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.